Brain Tumor Diagnostics Market By Diagnostic Type (Imaging Techniques {MRI (Magnetic Resonance Imaging), CT (Computed Tomography) Scan, PET (Positron Emission Tomography) Scan, Ultrasound, X-ray}, Biopsy Techniques {Needle Biopsy, Surgical Biopsy, Liquid Biopsy}, Molecular Diagnostics {Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH)}, Biomarker-based Tests), By Tumor Type (Primary Brain Tumors {Gliomas, Meningiomas, Pituitary Tumors, Medulloblastomas}, Secondary Brain Tumors {Lung Cancer Metastases, Breast Cancer Metastases, Melanoma Metastases, Colon Cancer Metastases}), By End-user (Hospitals & Clinics, Diagnostic Imaging Centers, Research & Academic Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Brain Tumor Diagnostics Market accounted for USD 2.93 Billion in 2024 and is expected to reach USD 7.3 Billion by 2035, growing at a CAGR of around 8.65% between 2025 and 2035. The Brain Tumor Diagnostics Market involves diagnostic methods related to brain tumors, inclusive of imaging systems (MRI, CT scans, PET), biopsy, molecular diagnostics, and liquid biopsy. The rising incidence of gliomas, the incorporation of artificial intelligence in diagnosis, and the rise in the use of noninvasive procedures are some of the factors fueling the market.

It is observed that the industry is experiencing growth in precise and accurate medicine and genetics tests for tumors. North America is leading the market because it has well-developed technology in the field of health care compared to the Asia-Pacific region, which is growing fast. These players comprise GE Healthcare, Siemens Healthineers, and Roche Diagnostics. The market is expected to have steadiness. The rising growth over the period arises from the newer technologies arriving in the markets and also the rising healthcare expenditure across the world.

Report Scope:

Market Dynamics

Rising brain tumor prevalence and increasing cases of brain tumors drive diagnostic demand.

The ever-growing symptoms of brain tumors are another crucial factor for the Brain Tumor Diagnostics Market because they boost the need for enhanced diagnosis. Increased incidence of both primary and metastatic brain tumors means that more awareness and early diagnostic programs are being developed. It has been attributed to factors such as a shift in lifestyle, heredity, and change in environmental conditions, among other causes. Availability of health services and an increase in programs for screening all around enhance diagnosis and, subsequently, better treatment. The use of MRI, CT scans, and liquid biopsies is emerging as new methods for a safer and more accurate diagnosis.

Another factor is that individuals who are aged can also be susceptible to brain tumors, thereby increasing the demand in the market. More accurate and efficient testing and diagnosis are improving due to technological developments in the use of artificial intelligence. Several healthcare facilities, such as hospitals, diagnostic centers, and institutions, are now using advanced technologies in the management of their patients. Industry transformation is the topic of the present article as the demand for personalized medicine and biomarker-based diagnostics continues to grow. Similarly, increasing the knowledge of patients and healthcare providers about the product is also fueling its demand in the global market. In total, the diagnostics segment of the brain tumor industry will remain on the rise owing to rising instances and advancing identification methods.

Advancements in imaging technology enhanced MRI, CT, and PET scans to improve accuracy.

Technological innovation in imaging diagnostic procedures is enhancing the solutions’ capability to identify brain tumors, thus enhancing dRI-enhanced demand. MRI, CT, and PET scans help in obtaining high-resolution images, which facilitate early diagnosis of the tumor. Modern MRI techniques like fMRI and DTI are useful in defining the areas of brain activity and position of the tumors. 3D CT reconstruction provides vital information that differentiates the tumor’s size, shape, and extent. With the use of PET and radiotracers, there are better diagnostic capabilities for the metabolism and function of a tumor and to distinguish neoplasms from benign growths. Artificial intelligence-enabled applications help in imaging diagnostics by eliminating time-consuming manual analysis of images that may contain errors.

Besides, supplementary imaging techniques and the use of contrast agents enhance the accuracy of tumor identification and localization in staging. The current growth of healthcare spending and prolific tie-ups between imaging-associated firms and research bodies are fostering innovation effectively. Advancements in early diagnostics, along with the need for more accurate diagnostic technologies to support precision medicine, are spurring new developments in imaging technology. In general, computer and molecular imaging technologies are bringing significant changes to the diagnosis of brain tumors that, in turn, enhance the patients’ lives.

High diagnostic costs and expensive imaging and molecular tests limit patient affordability.

One of the key factors that limit the growth of the Brain Tumor Diagnostics Market is the high diagnostic costs, including the expenses of MRI, CT, and PET scans. Another implies that accrual costs are directly associated with performance and sophistication since next-generation sequencing and liquid biopsy tests are more complicated and use cutting-edge technologies. These are very expensive, and unfortunately, many healthcare facilities, especially in developing countries, cannot afford such technologies; thus, their availability is restricted. Any individuals without access to proper medical insurance suffer from high out-of-pocket costs that often may prevent the timely and correct diagnosis of any tumor. The high costs also reduce the chances of timely screening, making most patients present themselves at the hospital in the late stages of the ailments, thus implying a worse prognosis.

Lack of sufficient government funding and getting reimbursements also pose a problem in acquiring diagnostics. Some of the factors said to include the high capital investment needed to establish the imaging and molecular testing facilities. As a result of that, advanced diagnostic technologies remain unavailable in such regions just because of the high cost of those products. The problem of cost also plays a negative role in a faster rate of adoption of innovations, thereby influencing market growth. The removal of cost-related issues through policy changes, insurance, and the development of technology is essential for accessibility to be more prevalent.

Higher prevalence fuels demand for advanced diagnostic tools.

The growing rate of people suffering from brain tumor diseases due to rapidly advancing age has fueled the need for effective diagnostic techniques. Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) are becoming more accurate in the location of the tumor. Liquid biopsy and molecular diagnostics are promising methods compared to invasive ones because they are effective but have minimal invasiveness. Artificial intelligence diagnostic tools are making diagnoses more accurate and reducing the number of interpretation or misdiagnosis cases. Governments and healthcare organizations are focusing on employing a considerable amount of budget for research and development of early detection systems. This paper will aim to analyze precision medicine and biomarker diagnostic methods to identify and classify tumors.

Lifestyle, enhanced use of alcohol, tobacco, and cigarettes, and radiation, among other environmental factors, are some of the causes of brain tumors, which are on the rise due to increased life expectancy. Emerging markets in Asia-Pacific and Latin America present lucrative growth opportunities for diagnostic companies. It has been evidenced that growth in the domain of genomic and proteomic studies has been adding to the development of the market even further. This has, in particular, been witnessed by the adoption of telemedicine and artificial intelligence diagnostics, which have enhanced the delivery of health care, particularly in remote areas. It is evident that with the constant increase in awareness and spending on healthcare, adequate, accurate, and timely diagnosis solutions for brain tumors will be needed.

Enhanced imaging interpretation and automated diagnostics improve accuracy.

Advanced imaging interpretation, as well as automation, also offer great value in the computerized diagnosis of brain tumors. The current imaging techniques include the use of MRI, CT, and PET scans that use advanced technology, including artificial intelligence. Specifically, computational intelligent models in the diagnosis of malignant tumors utilize big data to interpret large sample datasets. Self-service lowers the chances of errors made by humans while also expediting the diagnostic processes, thereby resulting in a shorter time to arrive at a clinical decision. AI’s incorporation in the field of radiology improves efficiency in the image reconstruction of anomalies as well as in the identification of the anomalies. This has the potential to enhance early diagnosis since AI-based decision support helps radiology specialists recognize barely discernible nuances regarding the tumor.

This way, deep learning models improve diagnostic accuracy as patterns can now be recognized more accurately and consistently. Machine-supported tissue diagnostics and analyzing tissue samples speed up cancer classification for personalized therapy. The use of AI in diagnosis is now cheaper than before and is also the reason behind the increased accessibility in the developing world. The use of imaging makes it possible for doctors and consultants to access reports from the comfort of their homes or even various clinics. With the enhancement of digitization processes, particularly in healthcare systems, automated diagnosis shall be used in health management. Reacting to the ongoing trends in AI and imaging technology, more development in the diagnostics of brain tumors is expected.

Industry Experts Opinion

“The company's efforts to address the treatment of aggressive brain cancers such as glioblastoma. Developing drugs that can penetrate the blood-brain barrier is a major challenge in treating CNS tumors. Their commitment to advancing targeted therapies aims to improve survival rates and outcomes for patients with these difficult-to-treat cancers.”

• John Climaco, CEO of CNS Pharmaceuticals

Segment Analysis

Based on the Diagnostic Type, the Brain Tumor Diagnostics Market is classified into MRI, CT, and PET scans, Health offers detailed examinations of tumors without actually going through surgery. This is because precision medicine and related novel treatment methods such as NGS and PCR are becoming popular. Biopsy remains essential in the accurate classification of tumors, and improvements in the techniques used for needle biopsy have aided in efficiency.

The noninvasive nature of liquid biopsy makes it appealing for early-stage diagnosis with small invasiveness to the patient. Health workers are increasingly adopting less invasive procedures for diagnosing diseases as the number of users in demand for such tests increases. Imaging techniques are also quite popular because of their ability to detect tumors in different stages, and molecular testing is used to determine the genetics of a tumor for treatment. These trends give rise to the growing use of one or an amalgamation of the diagnostic apparatus to attain the utmost therapeutic results.

Based on the Tumor type, the Brain Tumor Diagnostics Market is classified into primary and secondary or metastatic brain tumors. Some of the common types of brain tumors include gliomas, meningiomas, and pituitary tumors, which can be identified and classified using other imaging techniques, namely MRI, CT scans, and biopsy, among others. The portion of gliomas, including glioblastomas, is rather large among the primary tumors, which contributes to the increased need for improved imaging and molecular analysis.

Metastases, that is, tumors of the secondary type, may develop from lung, breast, or melanoma cancers, and for this reason, accurate diagnostic tests should be employed to identify metastatic growths. The early stages of diagnosis also show that both tumors can be positively benefited from innovations such as imaging through artificial intelligence and genetics. One of the largest segments for metastatic tumors is anticipated to grow due to growing incidences of cancer with brain relapse. These changes enhance the predictions made and determine the treatment plans for first- and secondarily established brain tumors.

Regional Analysis

The largest market share of brain tumor diagnostics is expected in North America, attributed to its well-developed healthcare system, high health spending, and Silicon Valley conference companies that include GE Healthcare and Siemens Healthineers. The U.S., in particular, benefits from a well-established healthcare system and significant investments in research and development for brain tumor diagnostics. Other factors that fuel the growth of this region include the adoption of the latest technologies, such as AI, for imaging and molecular tests. The availability of funds from the government influences changes in methodologies applied to diagnosing brain tumors. This has also been accompanied by the establishment of a sound regulatory environment to uphold the standards of diagnostic products in the region. That is why, with subjects such as personalized medicine gaining importance, North America is likely to retain the leading position for future years.

The information also indicates that in the Asia-Pacific region, diagnostics of brain tumors are likely to be the fastest-growing market. The key factors promoting the growth of this market include a growing number of patients suffering from brain tumors, rising awareness levels of health care, and the availability of enhanced diagnostic equipment in the region. The other reasons are the increased rate of growth in the cities, a continuously aging population, and changes in the structure of healthcare in countries like China, India, and Japan. The accessibility of garments is also increasing in terms of affordability and availability and is thus capable of reaching a wider number of patients. This is because as the region embraces advances in technology, the adoption of diagnostic solutions is bound to grow in demand as well. This is why this particular location will experience significant growth in the market, mainly due to the development of the healthcare sector and the emphasis on cancer diagnosis.

Competitive Landscape

The Global Brain Tumor Diagnostics Market is highly competitive, with many suppliers and new entrants who come up with new methods of imaging and molecular diagnostics or introduce the use of AI and machine learning. MR, CT, and PET scan leaders include GE Healthcare, Siemens Healthineers, Philips Healthcare, and Canon Medical Systems. The major companies that are already involved in various molecular testing and genetic profiling are Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, which provide essential tools for tumor detection and protocols.

Impacts of AI-based solutions include the establishment of more players in the industry market and products developed by start-ups and technology companies to develop various types of software to improve diagnostic proficiency. They also include shifts in market relations due to the adoption of cloud-based platforms and solutions that have enabled telemedicine with remote diagnostic capabilities. Thirdly, diagnostic companies are expanding in the regional markets in the developing parts of the world, such as Asia-Pacific and Latin America, adding more competition to these growing areas. Technological innovations, new product developments, strategic mergers and acquisitions, and consolidation are other significant strategies encouraged in this market.

Brain Tumor Diagnostics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, Enhertu demonstrated significant clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases in the largest prospective trial conducted in Europe, achieving a 61.6% progression-free survival rate.
• In May 2024, GE HealthCare launched AI-enhanced oncology solutions at the ESTRO 2024 Congress in Glasgow, aiming to streamline radiation therapy workflows and personalize cancer care for improved patient outcomes.
• In March 2024, AstraZeneca acquired Fusion to accelerate developments in cancer treatments. The acquisition focuses on replacing traditional treatments such as chemotherapy and radiotherapy with a modernized approach.
• In January 2024, GE HealthCare acquired MIM Software. This agreement facilitates MIM software with AI-enabled imaging and workflow tools across various sectors, such as oncology and neurology healthcare sectors.

Report Coverage:

By Diagnostic Type

• Imaging Techniques
  • MRI (Magnetic Resonance Imaging)
  • CT (Computed Tomography) Scan
  • PET (Positron Emission Tomography) Scan
  • Ultrasound
  • X-ray
• Biopsy Techniques
  • Needle Biopsy
  • Surgical Biopsy
  • Liquid Biopsy
• Molecular Diagnostics
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
• Biomarker-based Tests

By Tumor Type

• Primary Brain Tumors
  • Gliomas
  • Meningiomas
  • Pituitary Tumors
  • Medulloblastomas
• Secondary Brain Tumors
  • Lung Cancer Metastases
  • Breast Cancer Metastases
  • Melanoma Metastases
  • Colon Cancer Metastases

By End-User

• Hospitals & Clinics
• Diagnostic Imaging Centers
• Research & Academic Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• General Electric Healthcare Company
• Siemens Healthineers AG
• Philips Healthcare
• Canon Medical Systems Corporation
• Hitachi Medical Corporation
• Medtronic plc
• Fujifilm Holdings Corporation
• Schneider Electric SE
• Elekta AB
• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Mindray Medical International Limited
• Varian Medical Systems, Inc.
• Becton, Dickinson, and Company

Frequently Asked Questions (FAQs)